Emergent BioSolutions (NYSE:EBS) Securities Fraud Class Action: Throughout the class period, Defendants touted Emergent's deals to produce J&J's and AstraZeneca's vaccine candidates and its "proven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results